Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 21 studies | 52% ± 20% | |
lung | 20 studies | 47% ± 16% | |
peripheral blood | 17 studies | 30% ± 10% | |
eye | 12 studies | 49% ± 20% | |
intestine | 11 studies | 36% ± 21% | |
kidney | 10 studies | 41% ± 9% | |
liver | 7 studies | 34% ± 17% | |
heart | 6 studies | 44% ± 12% | |
uterus | 5 studies | 46% ± 21% | |
adipose | 5 studies | 48% ± 23% | |
lymph node | 5 studies | 33% ± 8% | |
breast | 5 studies | 42% ± 7% | |
placenta | 4 studies | 51% ± 22% | |
bone marrow | 4 studies | 35% ± 14% | |
skin | 4 studies | 36% ± 10% | |
prostate | 4 studies | 29% ± 6% | |
pancreas | 3 studies | 45% ± 20% | |
adrenal gland | 3 studies | 30% ± 10% | |
esophagus | 3 studies | 52% ± 23% | |
stomach | 3 studies | 41% ± 27% | |
thymus | 3 studies | 36% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 19455.57 | 21 / 21 | 100% | 45.27 | 502 / 504 |
lung | 100% | 34019.38 | 578 / 578 | 100% | 75.99 | 1150 / 1155 |
esophagus | 100% | 19162.79 | 1444 / 1445 | 99% | 37.67 | 182 / 183 |
uterus | 100% | 29256.82 | 170 / 170 | 99% | 40.48 | 454 / 459 |
breast | 100% | 21241.55 | 459 / 459 | 98% | 31.52 | 1097 / 1118 |
intestine | 100% | 19953.67 | 966 / 966 | 98% | 27.59 | 517 / 527 |
prostate | 100% | 22154.04 | 244 / 245 | 98% | 33.63 | 491 / 502 |
thymus | 100% | 20464.32 | 651 / 653 | 97% | 48.35 | 588 / 605 |
kidney | 100% | 22195.00 | 89 / 89 | 96% | 51.53 | 865 / 901 |
stomach | 99% | 14884.90 | 356 / 359 | 97% | 27.48 | 276 / 286 |
pancreas | 97% | 8426.65 | 318 / 328 | 98% | 42.21 | 175 / 178 |
brain | 96% | 12226.16 | 2530 / 2642 | 99% | 78.70 | 699 / 705 |
skin | 99% | 12087.00 | 1791 / 1809 | 92% | 33.64 | 432 / 472 |
adrenal gland | 100% | 12191.71 | 258 / 258 | 90% | 19.30 | 207 / 230 |
ovary | 100% | 27604.84 | 180 / 180 | 90% | 22.52 | 387 / 430 |
liver | 80% | 4994.43 | 181 / 226 | 62% | 14.27 | 251 / 406 |
blood vessel | 100% | 32582.38 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 35257.60 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.35 | 1 / 1 |
adipose | 100% | 21311.90 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 99% | 13131.79 | 851 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 28.89 | 44 / 45 |
muscle | 91% | 6279.76 | 728 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 38.89 | 26 / 29 |
peripheral blood | 83% | 13349.14 | 771 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 80% | 40.14 | 64 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0044314 | Biological process | protein K27-linked ubiquitination |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0140454 | Biological process | protein aggregate center assembly |
GO_0008150 | Biological process | biological_process |
GO_0005829 | Cellular component | cytosol |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | WSB1 |
Protein name | WD repeat and SOCS box-containing protein 1 (WSB-1) (SOCS box-containing WD protein SWiP-1) WD repeat and SOCS box containing 1 (cDNA FLJ59301, highly similar to WD repeat and SOCS box-containing protein 1) WD repeat and SOCS box containing 1 WD repeat and SOCS box containing 1 (cDNA FLJ58059, highly similar to WD repeat and SOCS box-containing protein 1) WD repeat and SOCS box-containing protein 1 |
Synonyms | SWIP1 |
Description | FUNCTION: Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes type II iodothyronine deiodinase/DIO2. Confers constitutive instability to HIPK2 through proteasomal degradation. . |
Accessions | ENST00000582208.1 J3QLM8 ENST00000262394.7 [Q9Y6I7-1] Q9Y6I7 J3KSQ3 J3KT03 B4DTL1 ENST00000427287.6 ENST00000584114.1 ENST00000583193.5 ENST00000348811.6 [Q9Y6I7-2] ENST00000581185.5 ENST00000583742.1 A0JLP1 J3KS88 J3KRG6 B4DGB8 ENST00000579733.5 J3KTB3 ENST00000581440.5 |